About Sudeep Pharma
Sudeep Pharma is a publicly listed company based in Vadodara (India). Sudeep Pharma is involved in pharmaceutical and nutrition sectors. Its Indian entity Sudeep Pharma Limited reported revenue of ₹511 Cr.
Company details
Sudeep Pharma is engaged in activities related to pharmaceuticals and nutrition. Specific details about sectors, solutions, or operations are not provided on the website. The company is associated with health and wellness through its branding.
- Headquarters Vadodara, India
- Stage Public
- Website sudeepgroup.com
- Legal Name Sudeep Pharma, Inc
- Date of Incorporation 21 Dec, 1989
Key Metrics
- Market Cap₹11,332 Cr
SUDEEPPHRM · NSE
- Share Price₹1,003.30
+0.26% today
- Revenue₹642 Cr
FY 2025-26 · +27.9% YoY
- EBITDA₹223 Cr
Margin 34.7%
- Net Profit₹173 Cr
FY 2025-26 · +24.3% YoY
- P/E (TTM)61.9x
P/B 12.8x
- ROE25.4%
ROCE 27.9%
- Debt / Equity0.21
Interest cover 4.1x
Associated legal entities of Sudeep Pharma
Sudeep Pharma operates through Sudeep Pharma Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sudeep Pharma Limited Listed CIN L24231GJ1989PLC013141 | Active | 21 Dec 1989 | Baroda, Gujarat | ₹511 Cr | 377 | 10 | View details |
Board of directors of Sudeep Pharma Limited (Sudeep Pharma)
Sudeep Pharma Limited is the primary company behind Sudeep Pharma. The board of Sudeep Pharma Limited currently have 8 directors; the longest-serving is Sujit Jaysukh Bhayani, appointed in 1995. 20 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sujit Jaysukh Bhayani DIN 01767427 | Managing Director | 01 Mar 1995 | 31 yrs 7 mo | Sudeep Pharma Limited |
| Shanil Sujit Bhayani DIN 08877823 | Whole-time director | 10 Dec 2021 | 4 yrs 10 mo | Sudeep Pharma Limited |
| Samaresh Parida DIN 01853823 | Director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Raghunandan Sathyanarayan Rao DIN 02263845 | Director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Sujit Gulati DIN 00177274 | Director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Reshma Suresh Patel DIN 00165162 | Director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Ajay Shrirang Kandelkar DIN 10773491 | Whole-time director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Milin Kaimas Mehta DIN 01297508 | Director | 26 Jun 2026 | 3 mo | Sudeep Pharma Limited |
People of Sudeep Pharma
45 people are tracked at Sudeep Pharma (6 in leadership, 39 in team).
| Name | Role | Group |
|---|---|---|
Aniruddha Deshpande | Head - Human Capital Management - Sudeep Group | Leadership |
Ketan Vyas | Group CFO | Leadership |
| Managing Director | Leadership | |
Pankaj Patil | General Manager Sales | Leadership |
Gaurav T. | General Manager | Leadership |
Bhavin Desai | Assistant General Manager | Leadership |
Purvesh Trivedi | Assistant Manager | Team |
Jay Parekh | Senior Technical Sales Manager | Team |
Kailas Gawle | Asst.manager Microbiology | Team |
Sonoo Kumar | Qc Microbiologyst | Team |
Kartik Jadeja | Export Executive | Team |
Bhavik Mandowara | Manager - Accounts And Finance | Team |
Chaitanya Prasad . | Technical Sales Manager | Team |
Payal Vaidya | QC Chemist | Team |
Rohit Nikam | Sr Manager International Marketing | Team |
Falguni Patil | Assistant Manager- Exports Marketing | Team |
Shreyal Pawar | Purchase Executive | Team |
Sunil Yadav | Manager | Team |
Rajdeep Rabari | Stores Executive | Team |
Dipen Patel | Executive Customer Service Representative | Team |
25 more people are available in the full profile.
Premium access
Complete people profiles for Sudeep Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sudeep Pharma
Sudeep Pharma is a publicly listed company on the NSE with ticker symbol SUDEEPPHRM in India. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNSE: SUDEEPPHRM
- Listed entitySudeep Pharma Limited
Financials of Sudeep Pharma
Exchange-reported figures of Sudeep Pharma Limited, the listed company behind Sudeep Pharma (NSE: SUDEEPPHRM).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹642 Cr
+27.9% YoY
EBITDA
₹223 Cr
+16.6% YoY
Profit After Tax
₹173 Cr
+24.3% YoY
Net Worth
₹883 Cr
+79.1% YoY
Total Assets
₹1,078 Cr
+70.5% YoY
Total Debt
₹150 Cr
+9.4% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 642 | 502 | 459 | 429 | 343 | 215 | 123 |
| Revenue growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| EBITDA | 223 | 191 | 182 | 90.16 | 67.47 | 44.08 | 25.38 |
| EBITDA margin | +34.7% | +38.1% | +39.7% | +21.0% | +19.7% | +20.5% | +20.6% |
| Profit before tax | 228 | 183 | 175 | 85.98 | 68.61 | 43.02 | 24.60 |
| Net profit | 173 | 139 | 133 | 62.38 | 50.08 | 33.27 | 18.04 |
| Net profit margin | +26.9% | +27.7% | +29.1% | +14.6% | +14.6% | +15.5% | +14.7% |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Balance sheet | |||||||
| Total assets | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Net worth | 883 | 493 | 356 | 223 | 163 | 114 | 80.95 |
| Total debt | 150 | 138 | 78.08 | 83.09 | 83.69 | 31.06 | 20.17 |
| Cash & bank | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Net working capital | 537 | 346 | 203 | 119 | 105 | 36.67 | 32.04 |
| Cash flow | |||||||
| Cash from operations | 69.55 | 48.73 | 65.69 | 48.40 | (2.98) | 35.28 | 9.87 |
| Cash from investing | (327) | (78.59) | (49.28) | (49.79) | (38.42) | (40.42) | (22.47) |
| Cash from financing | 247 | 52.70 | (12.74) | (9.78) | 50.92 | 13.00 | 12.45 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 158 | 182 | 172 | 163 | 125 | 158 | 116 | 149 |
| Revenue growth (YoY) | +26.7% | +15.7% | +49.2% | +9.3% | +55.9% | - | - | - |
| Other income | 5.45 | 6.42 | 6.84 | 10.17 | 5.16 | 3.76 | 2.44 | 1.87 |
| EBITDA | 54.91 | 62.60 | 59.98 | 55.47 | 43.88 | 58.78 | 39.30 | 63.47 |
| EBITDA margin | +34.7% | +34.3% | +34.8% | +34.1% | +35.1% | +37.3% | +34.0% | +42.7% |
| Depreciation | 4.00 | 3.88 | 3.86 | 3.81 | 3.25 | 2.83 | 2.67 | 2.58 |
| Interest | 2.06 | 2.44 | 1.17 | 2.28 | 1.71 | 1.85 | 1.41 | 1.05 |
| Profit before tax | 54.30 | 62.70 | 61.79 | 59.55 | 44.08 | 57.86 | 37.66 | 61.71 |
| Tax | 13.71 | 14.15 | 14.08 | 12.76 | 12.80 | 13.67 | 8.94 | 12.97 |
| Net profit | 40.59 | 48.55 | 47.71 | 46.79 | 31.28 | 44.19 | 28.72 | 48.74 |
| EPS (₹) | 3.59 | 4.38 | 4.29 | 4.20 | 2.84 | 4.07 | 2.65 | 4.49 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 339 | 357 | 344 | 404 | 345 | 218 |
| Revenue growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| EBITDA | 120 | 133 | 133 | 89.25 | 68.14 | 45.79 |
| EBITDA margin | +35.6% | +37.2% | +38.7% | +22.1% | +19.8% | +21.0% |
| Profit before tax | 145 | 129 | 132 | 90.77 | 70.40 | 44.96 |
| Net profit | 107 | 95.60 | 97.99 | 67.17 | 52.01 | 34.92 |
| Net profit margin | +31.7% | +26.8% | +28.5% | +16.6% | +15.1% | +16.0% |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Balance sheet | ||||||
| Total assets | 913 | 552 | 396 | 308 | 242 | 148 |
| Net worth | 786 | 430 | 335 | 237 | 168 | 116 |
| Total debt | 127 | 120 | 60.48 | 70.52 | 72.66 | 31.06 |
| Cash & bank | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Net working capital | 404 | 265 | 180 | 128 | 105 | 34.37 |
| Cash flow | ||||||
| Cash from operations | 96.02 | 59.15 | 59.05 | 42.31 | (5.33) | 35.81 |
| Cash from investing | (367) | (91.59) | (40.67) | (40.71) | (27.97) | (44.71) |
| Cash from financing | 242 | 54.20 | (16.14) | (10.11) | 39.98 | 13.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106 | 80.17 | 90.28 | 87.88 | 80.17 | 105 | 83.48 | 106 |
| Revenue growth (YoY) | +31.8% | -23.5% | +8.2% | -17.3% | +29.1% | - | - | - |
| Other income | 9.80 | 9.62 | 9.44 | 12.83 | 6.62 | 3.10 | 2.29 | 1.44 |
| Total expenses | 66.49 | 51.28 | 60.67 | 57.00 | 49.78 | 59.39 | 57.02 | 66.10 |
| EBITDA | 39.19 | 28.89 | 29.61 | 30.88 | 30.39 | 45.46 | 26.46 | 40.20 |
| EBITDA margin | +37.1% | +36.0% | +32.8% | +35.1% | +37.9% | +43.4% | +31.7% | +37.8% |
| Depreciation | 1.83 | 1.79 | 1.79 | 1.77 | 1.75 | 1.71 | 1.53 | 1.47 |
| Interest | 1.76 | 1.97 | 0.63 | 2.03 | 1.44 | 1.58 | 1.25 | 0.71 |
| Profit before tax | 45.40 | 34.75 | 36.63 | 39.91 | 33.82 | 45.27 | 25.97 | 39.46 |
| Tax | 11.58 | 8.98 | 9.76 | 10.17 | 8.63 | 12.15 | 5.34 | 10.02 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 20 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 158 | 182 | 172 | 163 | 125 | 158 | 116 | 149 |
| Revenue growth (YoY) | +26.7% | +15.7% | +49.2% | +9.3% | +55.9% | - | - | - |
| Other income | 5.45 | 6.42 | 6.84 | 10.17 | 5.16 | 3.76 | 2.44 | 1.87 |
| EBITDA | 54.91 | 62.60 | 59.98 | 55.47 | 43.88 | 58.78 | 39.30 | 63.47 |
| EBITDA margin | +34.7% | +34.3% | +34.8% | +34.1% | +35.1% | +37.3% | +34.0% | +42.7% |
| Depreciation | 4.00 | 3.88 | 3.86 | 3.81 | 3.25 | 2.83 | 2.67 | 2.58 |
| Interest | 2.06 | 2.44 | 1.17 | 2.28 | 1.71 | 1.85 | 1.41 | 1.05 |
| Profit before tax | 54.30 | 62.70 | 61.79 | 59.55 | 44.08 | 57.86 | 37.66 | 61.71 |
| Tax | 13.71 | 14.15 | 14.08 | 12.76 | 12.80 | 13.67 | 8.94 | 12.97 |
| Net profit | 40.59 | 48.55 | 47.71 | 46.79 | 31.28 | 44.19 | 28.72 | 48.74 |
| EPS (₹) | 3.59 | 4.38 | 4.29 | 4.20 | 2.84 | 4.07 | 2.65 | 4.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 642 | 502 | 459 | 429 | 343 | 215 | 123 |
| Revenue growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| Other income | 28.59 | 9.33 | 6.10 | 9.52 | 7.39 | 3.44 | 3.22 |
| Total expenses | 419 | 311 | 277 | 339 | 276 | 171 | 97.63 |
| Employee cost | 51.89 | 38.34 | 29.41 | 66.10 | 15.55 | 11.46 | 9.34 |
| EBITDA | 223 | 191 | 182 | 90.16 | 67.47 | 44.08 | 25.38 |
| EBITDA margin | +34.7% | +38.1% | +39.7% | +21.0% | +19.7% | +20.5% | +20.6% |
| Depreciation | 14.81 | 10.59 | 9.01 | 7.92 | 4.53 | 3.53 | 3.07 |
| Interest | 8.50 | 6.90 | 4.74 | 5.78 | 1.72 | 0.97 | 0.93 |
| Profit before tax | 228 | 183 | 175 | 85.98 | 68.61 | 43.02 | 24.60 |
| Tax | 53.79 | 44.12 | 41.63 | 23.66 | 18.43 | 9.68 | 6.56 |
| Net profit | 173 | 139 | 133 | 62.38 | 50.08 | 33.27 | 18.04 |
| Net profit margin | +26.9% | +27.7% | +29.1% | +14.6% | +14.6% | +15.5% | +14.7% |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.29 | 11.98 | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 |
| Reserves & surplus | 872 | 481 | 355 | 222 | 162 | 113 | 79.54 |
| Shareholders' funds (net worth) | 883 | 493 | 356 | 223 | 163 | 114 | 80.95 |
| Minority interest | 14.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 148 | 135 | 75.03 | 82.26 | 83.69 | 31.06 | 17.09 |
| Unsecured loans | 2.13 | 2.30 | 3.05 | 0.83 | 0.00 | 0.00 | 3.08 |
| Total debt | 150 | 138 | 78.08 | 83.09 | 83.69 | 31.06 | 20.17 |
| Total liabilities | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Assets | |||||||
| Gross block | 378 | 216 | 197 | 166 | 157 | 83.31 | 71.80 |
| Net block | 337 | 189 | 180 | 158 | 137 | 67.65 | 59.58 |
| Capital work in progress | 185 | 88.22 | 44.66 | 25.97 | 8.13 | 24.00 | 8.16 |
| Investments | 0.00 | 0.14 | 0.13 | 3.03 | 0.00 | 19.10 | 6.00 |
| Inventories | 216 | 129 | 66.58 | 71.00 | 36.54 | 17.47 | 9.50 |
| Sundry debtors | 228 | 185 | 145 | 93.71 | 107 | 55.18 | 30.32 |
| Cash & bank balances | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Loans & advances | 65.73 | 58.15 | 50.11 | 51.98 | 31.68 | 14.89 | 12.39 |
| Total current assets | 624 | 424 | 275 | 227 | 197 | 99.50 | 56.31 |
| Total current liabilities | 87.17 | 78.41 | 72.58 | 108 | 91.53 | 62.83 | 24.27 |
| Net working capital | 537 | 346 | 203 | 119 | 105 | 36.67 | 32.04 |
| Total assets | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 36.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 | 4.25 |
| Net cash from operating activities | 69.55 | 48.73 | 65.69 | 48.40 | (2.98) | 35.28 | 9.87 |
| Net cash from investing activities | (327) | (78.59) | (49.28) | (49.79) | (38.42) | (40.42) | (22.47) |
| Net cash from financing activities | 247 | 52.70 | (12.74) | (9.78) | 50.92 | 13.00 | 12.45 |
| Net change in cash | (10.07) | 22.83 | 3.67 | (11.17) | 9.52 | 7.86 | (0.16) |
| Closing cash | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| EBITDA growth | +16.6% | +4.7% | +102.4% | +33.6% | +53.1% | +73.7% | - |
| PBT growth | +24.7% | +4.6% | +103.3% | +25.3% | +59.5% | +74.9% | +9997.0% |
| Net income growth | +24.3% | +4.3% | +113.9% | +24.6% | +50.5% | +84.4% | - |
| Revenue CAGR (3Y) | +14.4% | +13.5% | +28.8% | +51.6% | - | - | - |
| EBITDA CAGR (3Y) | +35.2% | +41.5% | +60.6% | +52.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +27.1% | +27.6% | +29.0% | +14.5% | +14.6% | +15.5% | +14.7% |
| Return on capital employed | +27.9% | +35.5% | +48.4% | +33.1% | +35.7% | +35.4% | +25.0% |
| Return on net worth | +25.4% | +32.8% | +46.0% | +32.2% | +36.2% | +34.2% | +22.3% |
| Debt / equity | 0.21 | 0.25 | 0.28 | 0.43 | 0.41 | 0.26 | 0.25 |
| Long-term debt / equity | 0.06 | 0.06 | 0.06 | 0.13 | 0.15 | 0.11 | 0.10 |
| Interest cover | 4.09 | 3.82 | 2.73 | 7.03 | 2.73 | 2.39 | 4.17 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.16 | 2.43 | 2.53 | 2.65 | 2.86 | 2.77 | 1.71 |
| Inventory turnover | 3.73 | 5.14 | 6.68 | 7.97 | 12.70 | 15.95 | 12.95 |
| Debtors turnover | 3.11 | 3.04 | 3.85 | 4.27 | 4.23 | 5.03 | 4.06 |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 78.21 | 50.48 | 252.69 | 158.47 | 1,159.15 | 810.48 | 574.46 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106 | 80.17 | 90.28 | 87.88 | 80.17 | 105 | 83.48 | 106 |
| Revenue growth (YoY) | +31.8% | -23.5% | +8.2% | -17.3% | +29.1% | - | - | - |
| Other income | 9.80 | 9.62 | 9.44 | 12.83 | 6.62 | 3.10 | 2.29 | 1.44 |
| Total expenses | 66.49 | 51.28 | 60.67 | 57.00 | 49.78 | 59.39 | 57.02 | 66.10 |
| EBITDA | 39.19 | 28.89 | 29.61 | 30.88 | 30.39 | 45.46 | 26.46 | 40.20 |
| EBITDA margin | +37.1% | +36.0% | +32.8% | +35.1% | +37.9% | +43.4% | +31.7% | +37.8% |
| Depreciation | 1.83 | 1.79 | 1.79 | 1.77 | 1.75 | 1.71 | 1.53 | 1.47 |
| Interest | 1.76 | 1.97 | 0.63 | 2.03 | 1.44 | 1.58 | 1.25 | 0.71 |
| Profit before tax | 45.40 | 34.75 | 36.63 | 39.91 | 33.82 | 45.27 | 25.97 | 39.46 |
| Tax | 11.58 | 8.98 | 9.76 | 10.17 | 8.63 | 12.15 | 5.34 | 10.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 339 | 357 | 344 | 404 | 345 | 218 |
| Revenue growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| Other income | 38.50 | 8.38 | 8.20 | 11.18 | 8.08 | 3.67 |
| Total expenses | 218 | 224 | 211 | 315 | 277 | 172 |
| Employee cost | 28.95 | 26.06 | 20.22 | 60.79 | 13.55 | 11.46 |
| EBITDA | 120 | 133 | 133 | 89.25 | 68.14 | 45.79 |
| EBITDA margin | +35.6% | +37.2% | +38.7% | +22.1% | +19.8% | +21.0% |
| Depreciation | 7.11 | 6.12 | 5.15 | 4.83 | 4.19 | 3.53 |
| Interest | 6.73 | 5.68 | 3.68 | 4.83 | 1.63 | 0.97 |
| Profit before tax | 145 | 129 | 132 | 90.77 | 70.40 | 44.96 |
| Tax | 37.51 | 33.66 | 34.23 | 23.60 | 18.10 | 9.97 |
| Net profit | 107 | 95.60 | 97.99 | 67.17 | 52.01 | 34.92 |
| Net profit margin | +31.7% | +26.8% | +28.5% | +16.6% | +15.1% | +16.0% |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 11.29 | 11.98 | 1.41 | 1.41 | 1.41 | 1.41 |
| Reserves & surplus | 775 | 418 | 333 | 235 | 167 | 115 |
| Shareholders' funds (net worth) | 786 | 430 | 335 | 237 | 168 | 116 |
| Secured loans | 125 | 119 | 58.05 | 69.69 | 72.66 | 31.06 |
| Unsecured loans | 1.72 | 1.78 | 2.43 | 0.83 | 0.00 | 0.00 |
| Total debt | 127 | 120 | 60.48 | 70.52 | 72.66 | 31.06 |
| Total liabilities | 913 | 552 | 396 | 308 | 242 | 148 |
| Assets | ||||||
| Gross block | 124 | 120 | 106 | 94.64 | 139 | 83.31 |
| Net block | 102 | 105 | 95.89 | 89.82 | 120 | 67.65 |
| Capital work in progress | 161 | 87.71 | 43.50 | 25.59 | 4.38 | 23.21 |
| Investments | 32.07 | 31.51 | 28.75 | 18.70 | 15.11 | 24.21 |
| Inventories | 131 | 64.60 | 45.42 | 52.40 | 26.33 | 15.10 |
| Sundry debtors | 80.13 | 162 | 141 | 126 | 123 | 58.14 |
| Cash & bank balances | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Loans & advances | 157 | 40.70 | 35.40 | 47.81 | 27.71 | 14.86 |
| Total current assets | 458 | 313 | 231 | 233 | 192 | 96.29 |
| Total current liabilities | 53.75 | 48.20 | 50.96 | 105 | 86.61 | 61.92 |
| Net working capital | 404 | 265 | 180 | 128 | 105 | 34.37 |
| Total assets | 913 | 552 | 396 | 308 | 242 | 148 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 30.35 | 8.59 | 6.35 | 14.87 | 8.19 | 4.10 |
| Net cash from operating activities | 96.02 | 59.15 | 59.05 | 42.31 | (5.33) | 35.81 |
| Net cash from investing activities | (367) | (91.59) | (40.67) | (40.71) | (27.97) | (44.71) |
| Net cash from financing activities | 242 | 54.20 | (16.14) | (10.11) | 39.98 | 13.00 |
| Net change in cash | (28.16) | 21.75 | 2.24 | (8.52) | 6.68 | 4.09 |
| Closing cash | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| EBITDA growth | -9.3% | -0.1% | +48.9% | +31.0% | +48.8% | - |
| PBT growth | +12.1% | -2.2% | +45.7% | +28.9% | +56.6% | +9997.0% |
| Net income growth | +12.4% | -2.4% | +45.9% | +29.2% | +48.9% | - |
| Revenue CAGR (3Y) | -5.7% | +1.1% | +16.4% | - | - | - |
| EBITDA CAGR (3Y) | +10.5% | +24.9% | +42.7% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +31.8% | +26.8% | +28.5% | +16.6% | +15.2% | +16.1% |
| Return on capital employed | +20.7% | +28.5% | +38.7% | +34.8% | +37.0% | +36.7% |
| Return on net worth | +17.7% | +25.1% | +34.3% | +33.2% | +36.8% | +35.5% |
| Debt / equity | 0.20 | 0.24 | 0.23 | 0.35 | 0.36 | 0.26 |
| Long-term debt / equity | 0.06 | 0.06 | 0.03 | 0.07 | 0.11 | 0.11 |
| Interest cover | 5.94 | 4.48 | 2.88 | 5.72 | 2.55 | 2.30 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 2.77 | 3.16 | 3.43 | 3.46 | 3.11 | 2.81 |
| Inventory turnover | 3.47 | 6.48 | 7.03 | 10.26 | 16.65 | 17.71 |
| Debtors turnover | 2.79 | 2.35 | 2.57 | 3.24 | 3.81 | 4.93 |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 69.59 | 44.01 | 2,374.56 | 1,681.07 | 1,193.96 | 822.76 |
Web traffic of Sudeep Pharma
Websites that share an audience with Sudeep Pharma (sudeepgroup.com).
Similar websites
Websites whose visitors overlap most with Sudeep Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sudeeppharma.com | 100% | 10K | – | View details |
Upgrade to premium
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sudeep Pharma
Premium access
Complete news archive for Sudeep Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sudeep Pharma
Sudeep Pharma is headquartered in Vadodara, India. It is registered at Vadodara, Gujarat, India.
The primary company behind Sudeep Pharma, Sudeep Pharma Limited, reported revenue of ₹511 Cr for FY 2025, up 10% year on year.
Sudeep Pharma is engaged in activities related to pharmaceuticals and nutrition. Specific details about sectors, solutions, or operations are not provided on the website. The company is associated with health and wellness through its branding.
Yes, Sudeep Pharma is publicly traded on NSE under the ticker symbol SUDEEPPHRM.
Sudeep Pharma operates through Sudeep Pharma Limited.
The legal entities of Sudeep Pharma currently have 10 directors, including Shanil Sujit Bhayani, Sujit Jaysukh Bhayani, Dimple Ashwinbhai Mehta and others.